EPISODE · May 24, 2026 · 42 MIN
Introduction to Anti Amyloid Antibodies to Slow Alzheimer's Disease
from Confronting Dementia · host Travis Urban MD
First fully approved by the FDA in 2023, anti amyloid antibodies (lecanemab and donanemab) are the first class of medicines to definitively slow the progression of Alzheimer's Disease. Join me for a conversation with CPMC and Sutter Health's Dolby Center Medical Director Armen Moughamian MD, PhD to discuss what these exciting new treatments are, their potential benefits and risks, and which patients are good candidates for treatment. We also touch on some of the initial controversy surrounding these drugs and the clinical trials currently in progress using these medicines to potentially prevent Alzheimer's disease altogether! The episode is a great overview for anyone interested in learning more about the latest in Alzheimer's treatment.
Embed this episode
Ready to play
Introduction to Anti Amyloid Antibodies to Slow Alzheimer's Disease
No transcript for this episode yet
Similar Episodes
No similar episodes found.